Novavax Reports Positive Data for its Trivalent Seasonal Influenza (VLP) Vaccine Candidate

Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that the Company made a poster presentation on the "Safety and Immunogenicity of a Recombinant Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine in Healthy Adults" on Saturday, October 31, 2009 at the 47(th) Annual Meeting of the Infectious Diseases Society of America (IDSA).

This presentation included data from a study of Novavax's trivalent seasonal influenza VLP vaccine that began in May of this year among healthy adults 18 to 49 years of age. The vaccine contained VLPs matched to the influenza strains recommended for the 2008-2009 influenza vaccine including H1N1 A/Brisbane/59/2007, H3N2 A/Brisbane/10/2007, and B/Florida/04/2006. The study enrolled 241 subjects in total, including 221 who were randomized to receive either VLP vaccine at 15 mcg or 60 mcg or a placebo and 20 subjects who received an inactivated influenza vaccine (TIV).